Biofrontera Stock Performance
| BFRI Stock | USD 1.13 0.07 6.60% |
On a scale of 0 to 100, Biofrontera holds a performance score of 4. The firm shows a Beta (market volatility) of 0.94, which signifies possible diversification benefits within a given portfolio. Biofrontera returns are very sensitive to returns on the market. As the market goes up or down, Biofrontera is expected to follow. Please check Biofrontera's sortino ratio, skewness, price action indicator, as well as the relationship between the potential upside and rate of daily change , to make a quick decision on whether Biofrontera's price patterns will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Biofrontera are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite fairly inconsistent basic indicators, Biofrontera demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:20 | Last Split Date 2023-07-05 |
1 | Ovid Therapeutics Reports Q3 Loss, Tops Revenue Estimates | 11/12/2024 |
2 | ARMISTICE CAPITAL, LLC Acquires New Stake in Biofrontera Inc | 11/15/2024 |
3 | Acquisition by Hermann Luebbert of 190840 shares of Biofrontera subject to Rule 16b-3 | 11/29/2024 |
4 | Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz-Photodynamic Therapy In The Treatment Of Superficial Basal Cell Carcinoma | 01/08/2025 |
5 | Acquisition by Borer John J Iii of 22000 shares of Biofrontera subject to Rule 16b-3 | 01/24/2025 |
| Begin Period Cash Flow | 17.4 M |
Biofrontera |
Biofrontera Relative Risk vs. Return Landscape
If you would invest 100.00 in Biofrontera on November 4, 2024 and sell it today you would earn a total of 13.00 from holding Biofrontera or generate 13.0% return on investment over 90 days. Biofrontera is currently generating 0.4096% in daily expected returns and assumes 6.5604% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than Biofrontera, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Biofrontera Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biofrontera's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biofrontera, and traders can use it to determine the average amount a Biofrontera's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0624
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BFRI | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.56 actual daily | 58 58% of assets are less volatile |
Expected Return
| 0.41 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Biofrontera is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biofrontera by adding it to a well-diversified portfolio.
Biofrontera Fundamentals Growth
Biofrontera Stock prices reflect investors' perceptions of the future prospects and financial health of Biofrontera, and Biofrontera fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biofrontera Stock performance.
| Return On Equity | -1.49 | ||||
| Return On Asset | -0.4 | ||||
| Profit Margin | (0.38) % | ||||
| Operating Margin | (0.65) % | ||||
| Current Valuation | 8.14 M | ||||
| Shares Outstanding | 8.87 M | ||||
| Price To Book | 1.81 X | ||||
| Price To Sales | 0.28 X | ||||
| Revenue | 34.07 M | ||||
| Gross Profit | 16.82 M | ||||
| EBITDA | (18.45 M) | ||||
| Net Income | (20.13 M) | ||||
| Cash And Equivalents | 31.91 M | ||||
| Cash Per Share | 1.36 X | ||||
| Total Debt | 5.4 M | ||||
| Current Ratio | 3.16 X | ||||
| Book Value Per Share | 3.16 X | ||||
| Cash Flow From Operations | (24.89 M) | ||||
| Earnings Per Share | 1.16 X | ||||
| Market Capitalization | 10.03 M | ||||
| Total Asset | 27.93 M | ||||
| Retained Earnings | (99.65 M) | ||||
| Working Capital | 4.99 M | ||||
About Biofrontera Performance
By evaluating Biofrontera's fundamental ratios, stakeholders can gain valuable insights into Biofrontera's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biofrontera has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biofrontera has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 262.48 | 246.84 | |
| Return On Tangible Assets | (0.91) | (0.96) | |
| Return On Capital Employed | (2.65) | (2.52) | |
| Return On Assets | (0.83) | (0.87) | |
| Return On Equity | (4.83) | (4.59) |
Things to note about Biofrontera performance evaluation
Checking the ongoing alerts about Biofrontera for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biofrontera help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biofrontera had very high historical volatility over the last 90 days | |
| Biofrontera may become a speculative penny stock | |
| Biofrontera has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 34.07 M. Net Loss for the year was (20.13 M) with profit before overhead, payroll, taxes, and interest of 16.82 M. | |
| Biofrontera currently holds about 31.91 M in cash with (24.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Biofrontera has a frail financial position based on the latest SEC disclosures | |
| Roughly 32.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz-Photodynamic Therapy In The Treatment Of Superficial Basal Cell Carcinoma |
- Analyzing Biofrontera's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biofrontera's stock is overvalued or undervalued compared to its peers.
- Examining Biofrontera's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biofrontera's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biofrontera's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biofrontera's stock. These opinions can provide insight into Biofrontera's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Biofrontera Stock analysis
When running Biofrontera's price analysis, check to measure Biofrontera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biofrontera is operating at the current time. Most of Biofrontera's value examination focuses on studying past and present price action to predict the probability of Biofrontera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biofrontera's price. Additionally, you may evaluate how the addition of Biofrontera to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |